46
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Variation in pre-PCR processing of FFPE samples leads to discrepancies in BRAF and EGFR mutation detection: a diagnostic RING trial

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Aims

          Mutation detection accuracy has been described extensively; however, it is surprising that pre-PCR processing of formalin-fixed paraffin-embedded (FFPE) samples has not been systematically assessed in clinical context. We designed a RING trial to (i) investigate pre-PCR variability, (ii) correlate pre-PCR variation with EGFR/BRAF mutation testing accuracy and (iii) investigate causes for observed variation.

          Methods

          13 molecular pathology laboratories were recruited. 104 blinded FFPE curls including engineered FFPE curls, cell-negative FFPE curls and control FFPE tissue samples were distributed to participants for pre-PCR processing and mutation detection. Follow-up analysis was performed to assess sample purity, DNA integrity and DNA quantitation.

          Results

          Rate of mutation detection failure was 11.9%. Of these failures, 80% were attributed to pre-PCR error. Significant differences in DNA yields across all samples were seen using analysis of variance (p<0.0001), and yield variation from engineered samples was not significant (p=0.3782). Two laboratories failed DNA extraction from samples that may be attributed to operator error. DNA extraction protocols themselves were not found to contribute significant variation. 10/13 labs reported yields averaging 235.8 ng (95% CI 90.7 to 380.9) from cell-negative samples, which was attributed to issues with spectrophotometry. DNA measurements using Qubit Fluorometry demonstrated a median fivefold overestimation of DNA quantity by Nanodrop Spectrophotometry. DNA integrity and PCR inhibition were factors not found to contribute significant variation.

          Conclusions

          In this study, we provide evidence demonstrating that variation in pre-PCR steps is prevalent and may detrimentally affect the patient's ability to receive critical therapy. We provide recommendations for preanalytical workflow optimisation that may reduce errors in down-stream sequencing and for next-generation sequencing library generation.

          Related collections

          Most cited references10

          • Record: found
          • Abstract: found
          • Article: not found

          Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications.

          Mutations in codons 12 and 13 of the KRAS oncogene are relatively common in colorectal and lung adenocarcinomas. Recent data indicate that these mutations result in resistance to anti-epidermal growth factor receptor therapy. Therefore, we assessed Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS codon 12/13 mutations in formalin-fixed paraffin-embedded samples, including 58 primary and 42 metastatic colorectal adenocarcinomas, 63 primary and 17 metastatic lung adenocarcinomas, and 20 normal colon samples. Of 180 tumor samples, 62.2% were KRAS mutant positive, and 37.8% were negative. Melting curve analysis yielded no false positive or false negative results, but had 10% equivocal calls. Melting curve analysis also resulted in 4 cases with melting curves inconsistent with either wild-type or codon 12/13 mutations. These patterns were generated from samples with double mutants in codons 12/13 and with mutations outside of codons 12/13. Pyrosequencing yielded no false positive or false negative results as well. However, two samples from one patient yielded a pyrogram that was flagged as abnormal, but the mutation subtype could not be determined. Finally, using an electronic cutoff of 10%, Sanger sequencing showed 11.1% false positives and 6.1% false negatives. In our hands, the limit of detection for Sanger sequencing, pyrosequencing, and melting curve analysis was approximately 15 to 20%, 5%, and 10% mutant alleles, respectively.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            SPUD: a quantitative PCR assay for the detection of inhibitors in nucleic acid preparations.

              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Validity of nucleic acid purities monitored by 260nm/280nm absorbance ratios.

              J Glasel (1994)
                Bookmark

                Author and article information

                Journal
                J Clin Pathol
                J. Clin. Pathol
                jclinpath
                jcp
                Journal of Clinical Pathology
                BMJ Publishing Group (BMA House, Tavistock Square, London, WC1H 9JR )
                0021-9746
                1472-4146
                February 2015
                27 November 2014
                : 68
                : 2
                : 111-118
                Affiliations
                [1 ]Division of Surgery and Interventional Sciences, University College London , London, UK
                [2 ]University College London Advanced Diagnostics, University College London , London, UK
                [3 ]Division of Research Oncology, Guy's and St. Thomas’ Hospital NHS Trust , London, UK
                [4 ]Department of Pathology, Stanford University Medical Center , Stanford, USA
                [5 ]Department of Pathology, Northwestern University Feinberg School of Medicine , Chicago, USA
                [6 ]Department of Molecular and Human Genetics, Baylor College of Medicine , Houston, USA
                [7 ]Department of Pathology, Dartmouth Hitchcock Medical Center , Lebanon, USA
                [8 ]Institute of Cancer Research, The Royal Marsden Hospital NHS Trust , London, UK
                [9 ]Department of Pathology, University of Nebraska Medical Center , Omaha, USA
                [10 ]Regional Genetics Laboratory, Central Manchester University Hospital NHS Trust , Manchester, UK
                [11 ]Department of Pathology and Laboratory Medicine, UCLA School of Medicine , Los Angeles, USA
                [12 ]Paediatric Malignancy Department, Great Ormond Street Hospital for Children NHS Trust , London, UK
                [13 ]All Wales Genetics Laboratory, Cardiff and Vale NHS Trust , Cardiff, UK
                [14 ]Pathology and Tumour biology, University of Leeds, Leeds, UK
                [15 ]Asuragen , Austin, USA
                Author notes
                [Correspondence to ] Dr Rifat A Hamoudi, Division of Surgery and Interventional Science. University College London, 67-73 Riding House Street, London, W1W 7EJ, UK; r.hamoudi@ 123456ucl.ac.uk

                GJL and RAH contributed equally

                Article
                jclinpath-2014-202644
                10.1136/jclinpath-2014-202644
                4316935
                25430497
                c4ea0ec1-3589-4d80-a96c-59dc20b962ef
                Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions

                This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

                History
                : 4 September 2014
                : 9 October 2014
                : 9 October 2014
                Categories
                Original Article
                1506
                Custom metadata
                unlocked

                Pathology
                pcr,molecular pathology,diagnostic screening,melanoma,lung cancer
                Pathology
                pcr, molecular pathology, diagnostic screening, melanoma, lung cancer

                Comments

                Comment on this article